• Je něco špatně v tomto záznamu ?

Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases

M. Miglianico, M. Eldering, H. Slater, N. Ferguson, P. Ambrose, RS. Lees, KMJ. Koolen, K. Pruzinova, M. Jancarova, P. Volf, CJM. Koenraadt, HP. Duerr, G. Trevitt, B. Yang, AK. Chatterjee, J. Wisler, A. Sturm, T. Bousema, RW. Sauerwein, PG....

. 2018 ; 115 (29) : E6920-E6926. [pub] 20180702

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033023
E-zdroje Online Plný text

NLK Free Medical Journals od 1915 do Před 6 měsíci
Freely Accessible Science Journals od 1915 do Před 6 měsíci
PubMed Central od 1915 do Před 6 měsíci
Europe PubMed Central od 1915 do Před 6 měsíci
Open Access Digital Library od 1915-01-01
Open Access Digital Library od 1915-01-15

Odkazy

PubMed 29967151
DOI 10.1073/pnas.1801338115
Knihovny.cz E-zdroje

Isoxazolines are oral insecticidal drugs currently licensed for ectoparasite control in companion animals. Here we propose their use in humans for the reduction of vector-borne disease incidence. Fluralaner and afoxolaner rapidly killed Anopheles, Aedes, and Culex mosquitoes and Phlebotomus sand flies after feeding on a drug-supplemented blood meal, with IC50 values ranging from 33 to 575 nM, and were fully active against strains with preexisting resistance to common insecticides. Based on allometric scaling of preclinical pharmacokinetics data, we predict that a single human median dose of 260 mg (IQR, 177-407 mg) for afoxolaner, or 410 mg (IQR, 278-648 mg) for fluralaner, could provide an insecticidal effect lasting 50-90 days against mosquitoes and Phlebotomus sand flies. Computational modeling showed that seasonal mass drug administration of such a single dose to a fraction of a regional population would dramatically reduce clinical cases of Zika and malaria in endemic settings. Isoxazolines therefore represent a promising new component of drug-based vector control.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033023
003      
CZ-PrNML
005      
20181010125503.0
007      
ta
008      
181008s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1073/pnas.1801338115 $2 doi
035    __
$a (PubMed)29967151
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Miglianico, Marie $u TropIQ Health Sciences, 6534 Nijmegen, The Netherlands.
245    10
$a Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases / $c M. Miglianico, M. Eldering, H. Slater, N. Ferguson, P. Ambrose, RS. Lees, KMJ. Koolen, K. Pruzinova, M. Jancarova, P. Volf, CJM. Koenraadt, HP. Duerr, G. Trevitt, B. Yang, AK. Chatterjee, J. Wisler, A. Sturm, T. Bousema, RW. Sauerwein, PG. Schultz, MS. Tremblay, KJ. Dechering,
520    9_
$a Isoxazolines are oral insecticidal drugs currently licensed for ectoparasite control in companion animals. Here we propose their use in humans for the reduction of vector-borne disease incidence. Fluralaner and afoxolaner rapidly killed Anopheles, Aedes, and Culex mosquitoes and Phlebotomus sand flies after feeding on a drug-supplemented blood meal, with IC50 values ranging from 33 to 575 nM, and were fully active against strains with preexisting resistance to common insecticides. Based on allometric scaling of preclinical pharmacokinetics data, we predict that a single human median dose of 260 mg (IQR, 177-407 mg) for afoxolaner, or 410 mg (IQR, 278-648 mg) for fluralaner, could provide an insecticidal effect lasting 50-90 days against mosquitoes and Phlebotomus sand flies. Computational modeling showed that seasonal mass drug administration of such a single dose to a fraction of a regional population would dramatically reduce clinical cases of Zika and malaria in endemic settings. Isoxazolines therefore represent a promising new component of drug-based vector control.
650    _2
$a zvířata $7 D000818
650    _2
$a kontrola infekčních nemocí $x metody $7 D003140
650    _2
$a Culicidae $x růst a vývoj $7 D009033
650    _2
$a lidé $7 D006801
650    _2
$a insekticidy $x farmakologie $7 D007306
650    _2
$a moskyti - kontrola $x metody $7 D009032
650    _2
$a komáří přenašeči $x růst a vývoj $7 D000072138
650    _2
$a Psychodidae $x růst a vývoj $7 D011576
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Eldering, Maarten $u TropIQ Health Sciences, 6534 Nijmegen, The Netherlands.
700    1_
$a Slater, Hannah $u MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London SW7 2AZ, United Kingdom.
700    1_
$a Ferguson, Neil $u MRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London SW7 2AZ, United Kingdom.
700    1_
$a Ambrose, Pauline $u The Liverpool Insect Testing Establishment, Liverpool School of Tropical Medicine, Liverpool L3 5QA, United Kingdom.
700    1_
$a Lees, Rosemary S $u The Liverpool Insect Testing Establishment, Liverpool School of Tropical Medicine, Liverpool L3 5QA, United Kingdom.
700    1_
$a Koolen, Karin M J $u TropIQ Health Sciences, 6534 Nijmegen, The Netherlands.
700    1_
$a Pruzinova, Katerina $u Department of Parasitology, Faculty of Science, Charles University, 116 36 Prague, Czech Republic.
700    1_
$a Jancarova, Magdalena $u Department of Parasitology, Faculty of Science, Charles University, 116 36 Prague, Czech Republic.
700    1_
$a Volf, Petr $u Department of Parasitology, Faculty of Science, Charles University, 116 36 Prague, Czech Republic.
700    1_
$a Koenraadt, Constantianus J M $u Laboratory of Entomology, Wageningen University and Research, 6700 Wageningen, The Netherlands.
700    1_
$a Duerr, Hans-Peter $u Numerus Ltd., RG40 2AY Tübingen, Germany.
700    1_
$a Trevitt, Graham $u XenoGesis Ltd., Nottingham NG1 1GF, United Kingdom.
700    1_
$a Yang, Baiyuan $u California Institute for Biomedical Research, La Jolla, CA 92037.
700    1_
$a Chatterjee, Arnab K $u California Institute for Biomedical Research, La Jolla, CA 92037.
700    1_
$a Wisler, John $u California Institute for Biomedical Research, La Jolla, CA 92037.
700    1_
$a Sturm, Angelika $u TropIQ Health Sciences, 6534 Nijmegen, The Netherlands.
700    1_
$a Bousema, Teun $u Department of Medical Microbiology, Radboud University Medical Center, 6525 Nijmegen, The Netherlands.
700    1_
$a Sauerwein, Robert W $u TropIQ Health Sciences, 6534 Nijmegen, The Netherlands. Department of Medical Microbiology, Radboud University Medical Center, 6525 Nijmegen, The Netherlands.
700    1_
$a Schultz, Peter G $u California Institute for Biomedical Research, La Jolla, CA 92037; schultz@calibr.org mtremblay@calibr.org k.dechering@tropiq.nl.
700    1_
$a Tremblay, Matthew S $u California Institute for Biomedical Research, La Jolla, CA 92037; schultz@calibr.org mtremblay@calibr.org k.dechering@tropiq.nl.
700    1_
$a Dechering, Koen J $u TropIQ Health Sciences, 6534 Nijmegen, The Netherlands; schultz@calibr.org mtremblay@calibr.org k.dechering@tropiq.nl.
773    0_
$w MED00010472 $t Proceedings of the National Academy of Sciences of the United States of America $x 1091-6490 $g Roč. 115, č. 29 (2018), s. E6920-E6926
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29967151 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181010125953 $b ABA008
999    __
$a ok $b bmc $g 1340773 $s 1030017
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 115 $c 29 $d E6920-E6926 $e 20180702 $i 1091-6490 $m Proceedings of the National Academy of Sciences of the United States of America $n Proc Natl Acad Sci U S A $x MED00010472
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

    Možnosti archivace